Browse > Article
http://dx.doi.org/10.3340/jkns.2015.58.3.205

Effects of an Epithelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Add-on in Stereotactic Radiosurgery for Brain Metastases Originating from Non-Small-Cell Lung Cancer  

Kim, Hyun Jung (Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine)
Kim, Woo Sung (Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine)
Kwon, Do Hoon (Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine)
Cho, Young Hyun (Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine)
Choi, Chang-Min (Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine)
Publication Information
Journal of Korean Neurosurgical Society / v.58, no.3, 2015 , pp. 205-210 More about this Journal
Abstract
Objective : This study was aimed at optimizing the treatment of non-small-cell lung cancer (NSCLC) patients who are candidates for stereotactic radiosurgery (SRS) for brain metastases and harbor activating epithelial growth factor receptor (EGFR) mutations. Methods : We retrospectively reviewed the medical records from 2005 to 2010 of NSCLC patients with brain metastases harboring an activating EGFR mutation. Patients who received a combination therapy of SRS and EGFR-tyrosine kinase inhibitor (TKI) for brain metastases and those who received SRS without EGFR-TKI were compared. The primary endpoint was progression-free survival (PFS) of the brain metastases. Results : Thirty-one patients were eligible for enrolment in this study (SRS with TKI, 18; SRS without TKI, 13). Twenty-two patients (71.0%) were women and the median overall age was 56.0 years. PFS of brain lesions was not significantly prolonged in SRS with TKI treatment group than in SRS without TKI group (17.0 months vs. 9.0 months, p=0.45). Local tumor control rate was 83.3% in the combination therapy group, and 61.5% in the SRS monotherapy group (p=0.23). There were no severe adverse events related with treatment in both groups. Conclusions : Therapeutic outcome of concurrent SRS and TKI treatment was not superior to SRS monotherapy, however, there was no additive adverse events related with combined treatment.
Keywords
Radiosurgery; Neoplasm metastasis; Epiderrmal growth factor; Non-small-cell lung; Carcinoma;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, et al. : Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases : a randomized controlled trial. JAMA 295 : 2483-2491, 2006   DOI
2 Ceresoli GL, Cappuzzo F, Gregorc V, Bartolini S, Crino L, Villa E : Gefitinib in patients with brain metastases from non-small-cell lung cancer : a prospective trial. Ann Oncol 15 : 1042-1047, 2004   DOI
3 Clarke JL, Pao W, Wu N, Miller VA, Lassman AB : High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 99 : 283-286, 2010   DOI
4 Grommes C, Oxnard GR, Kris MG, Miller VA, Pao W, Holodny AI, et al. : "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol 13 : 1364-1369, 2011   DOI
5 Heon S, Yeap BY, Britt GJ, Costa DB, Rabin MS, Jackman DM, et al. : Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res 16 : 5873-5882, 2010   DOI
6 Hotta K, Kiura K, Ueoka H, Tabata M, Fujiwara K, Kozuki T, et al. : Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer 46 : 255-261, 2004   DOI
7 Kim HS, Koh EJ, Choi HY : Multiple gamma knife radiosurgery for multiple metachronous brain metastases associated with lung cancer : survival time. J Korean Neurosurg Soc 52 : 334-338, 2012   DOI
8 Kim MK, Lee KH, Lee JK, Choi JH, Hyun MS : Gefitinib is also active for carcinomatous meningitis in NSCLC. Lung Cancer 50 : 265-269, 2005   DOI
9 Kocher M, Soffietti R, Abacioglu U, Villa S, Fauchon F, Baumert BG, et al. : Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases : results of the EORTC 22952-26001 study. J Clin Oncol 29 : 134-141, 2011
10 Kuiper JL, Smit EF : High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases--one with a remarkable thoracic response as well. Lung Cancer 80 : 102-105, 2013   DOI
11 Langer CJ, Mehta MP : Current management of brain metastases, with a focus on systemic options. J Clin Oncol 23 : 6207-6219, 2005   DOI
12 Ma S, Xu Y, Deng Q, Yu X : Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population. Lung Cancer 65 : 198-203, 2009   DOI
13 Minniti G, Esposito V, Clarke E, Scaringi C, Bozzao A, Lanzetta G, et al. : Stereotactic radiosurgery in elderly patients with brain metastases. J Neurooncol 111 : 319-325, 2013   DOI
14 Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, et al. : Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23 : 2513-2520, 2005   DOI
15 Namba Y, Kijima T, Yokota S, Niinaka M, Kawamura S, Iwasaki T, et al. : Gefitinib in patients with brain metastases from non-small-cell lung cancer : review of 15 clinical cases. Clin Lung Cancer 6 : 123-128, 2004   DOI
16 National Comprehensive Cancer Network I : National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology Non-Small Cell lung cancer. Washington DC : National Comprehensive Cancer Network, 2014
17 Sheehan JP, Sun MH, Kondziolka D, Flickinger J, Lunsford LD : Radiosurgery for non-small cell lung carcinoma metastatic to the brain : long-term outcomes and prognostic factors influencing patient survival time and local tumor control. J Neurosurg 97 : 1276-1281, 2002   DOI
18 Park BJ, Lim YJ, Kim TS, Rhee BA, Leem W, Kim GK : Brain metastasis from lung cancer-treatment and prognosis-. J Korean Neurosurg Soc 27 : 53-58, 1998
19 Park SJ, Kim HT, Lee DH, Kim KP, Kim SW, Suh C, et al. : Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer 77 : 556-560, 2012   DOI
20 Porta R, Sanchez-Torres JM, Paz-Ares L, Massuti B, Reguart N, Mayo C, et al. : Brain metastases from lung cancer responding to erlotinib : the importance of EGFR mutation. Eur Respir J 37 : 624-631, 2011   DOI
21 Siegel R, Ma J, Zou Z, Jemal A : Cancer statistics, 2014. CA Cancer J Clin 64 : 9-29, 2014   DOI
22 Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. : New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 : 205-216, 2000   DOI
23 Tsao MN, Lloyd NS, Wong RK, Rakovitch E, Chow E, Laperriere N, et al. : Radiotherapeutic management of brain metastases : a systematic review and meta-analysis. Cancer Treat Rev 31 : 256-273, 2005   DOI
24 Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, et al. : Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol 31 : 895-902, 2013   DOI
25 Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, et al. : Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23 : 6829-6837, 2005   DOI
26 Kim ST, Uhm JE, Lee J, Sun JM, Sohn I, Kim SW, et al. : Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Lung Cancer 75 : 82-88, 2012   DOI
27 Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. : Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405) : an open label, randomised phase 3 trial. Lancet Oncol 11 : 121-128, 2010   DOI